

1FW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re provisional patent application of:

Kazuo KUMAGAI *et al.*

Appln. No. 10/502,453

Filed: January 12, 2005

For: NOVEL COMPOUNDS AS SEMAPHORIN  
INHIBITORS

Art Unit: To Be Assigned

Examiner: To Be Assigned

Confirmation No. 3688

Att'y Docket No. 31671-205693

Customer No.  
26694  
PATENT TRADEMARK OFFICE

**Request for Corrected Filing Receipt**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


**Mail Stop: Office of Initial Patent Examination  
Filing Receipt Corrections**


Sir:

Submitted herewith is the Filing Receipt for the above-referenced application, marked up (in red) to show an error in the Power of Attorney ("Robert Kinberg--26924" should read --The patent practitioners associated with Customer Number 26694--). Please issue a Corrected Filing Receipt for this application to reflect this change.

Respectfully submitted,

Dated: 4/13/05

  
Robert Kinberg  
Registration No. 26,924  
VENABLE LLP  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Telefax : (202) 344-8300



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,453	01/12/2005	1653	1528	31671-205693	8	37	5

B2K

CONFIRMATION NO. 3688

26694

VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP  
 P.O. BOX 34385  
 WASHINGTON, DC 20043-9998

## FILING RECEIPT



\*OC000000015215054\*

Date Mailed: 02/23/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Kazuo Kumagai, Hyogo, JAPAN;  
 Nobuo Hosotani, Hyogo, JAPAN;

*Corr filing receipt*  
 DOCKETED

Power of Attorney: The patent practitioners

~~Robert Kinberg 20924~~

associated with

Customer Number 26694

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/00567 01/22/2003

## Foreign Applications

JAPAN 2002-15216 01/24/2002


Projected Publication Date: 05/26/2005

Non-Publication Request: No

Early Publication Request: No

Title

31671-205693  
 CLIENT/MATTER # 205693 ATTY B2K  
 DUE DATE March 25, 2005  
 FINAL DEADLINE  
 DKTED BY *mes*



Novel compounds as semaphorin inhibitors

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).